Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice

Jia,Fang; Wu,Chunfang; Chen,Zhenyue; Lu,Guoping; Sun,Jianhui

doi:10.3892/mmr.2016.4975

Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice

Authors:
- Fang Jia
- Chunfang Wu
- Zhenyue Chen
- Guoping Lu
- Jianhui Sun
View Affiliations

Affiliations: Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
Published online on: March 3, 2016 https://doi.org/10.3892/mmr.2016.4975
Pages: 3574-3580

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endoplasmic reticulum (ER) stress has been suggested to play a role in the progression of plaque vulnerability and the occurrence of acute complications of coronary atherosclerosis. Atorvastatin is known to exert pleiotropic effects on the cardiovascular system. The present study aimed to examine the stabilizing effects of atorvastatin on vulnerable plaques within hyperhomocysteinemic apolipoprotein E‑deficient (ApoE‑/‑) mice, and to investigate the potential mechanisms underlying ER stress in ApoE‑/‑ mice and macrophages. In the present study, ApoE‑/‑ mice were administrated methionine or atorvastatin, and were sacrificed after 2 months. Necrotic core size, collagen content and inflammatory cytokine infiltration were subsequently measured in the aortic lesions, in order to investigate plaque stability. Treatment with atorvastatin decreased the number and size of necrotic cores, increased collagen content, and downregulated tumor necrosis factor (TNF)‑α and matrix metalloproteinase (MMP)‑9 mRNA expression, as compared with the methionine group. Immunohistochemical analysis indicated that atorvastatin administration prevented ER stress activation in aortic lesions of hyperhomocysteinemic mice. Furthermore, macrophages were challenged with homocysteine (Hcy) in the presence or absence of atorvastatin and thapsigargin (an ER stress inducer). Atorvastatin suppressed Hcy‑induced ER stress, and downregulated TNF‑α and MMP‑9 mRNA expression in the macrophages. Conversely, thapsigargin attenuated the inhibitory effects of atorvastatin against Hcy‑induced TNF‑α and MMP‑9 expression. These results indicated that hyperhomocysteinemia may promote atherosclerotic plaque development and instability. In addition, atorvastatin was able to improve atherosclerotic plaque stability in hyperhomocysteinemic mice by inhibiting ER stress.

View Figures

View References

1	Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E and Soehnlein O: Atherosclerotic plaque destabilization: Mechanisms, models, and therapeutic strategies. Circ Res. 114:214–226. 2014. View Article : Google Scholar : PubMed/NCBI
2	Hopkins PN: Molecular biology of atherosclerosis. Physiol Rev. 93:1317–1542. 2013. View Article : Google Scholar : PubMed/NCBI
3	Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, Aucouturier P, Chapman MJ and Lesnik P: Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation. 119:1795–1804. 2009. View Article : Google Scholar : PubMed/NCBI
4	Tabas I: The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res. 107:839–850. 2010. View Article : Google Scholar : PubMed/NCBI
5	Yao S, Miao C, Tian H, Sang H, Yang N, Jiao P, Han J, Zong C and Qin S: Endoplasmic reticulum stress promotes macrophage-derived foam cell formation by up-regulating cluster of differentiation 36 (CD36) expression. J Biol Chem. 289:4032–4042. 2014. View Article : Google Scholar :
6	Gao J, Ishigaki Y, Yamada T, Kondo K, Yamaguchi S, Imai J, Uno K, Hasegawa Y, Sawada S, Ishihara H, et al: Involvement of endoplasmic stress protein C/EBP homologous protein in arteriosclerosis acceleration with augmented biological stress responses. Circulation. 124:830–839. 2011. View Article : Google Scholar : PubMed/NCBI
7	McAlpine CS, Bowes AJ, Khan MI, Shi Y and Werstuck GH: Endoplasmic reticulum stress and glycogen synthase kinase-3β activation in apolipoprotein E-deficient mouse models of accelerated atherosclerosis. Arterioscler Thromb Vasc Biol. 32:82–91. 2012. View Article : Google Scholar
8	Zhou J and Austin RC: Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. Biofactors. 35:120–129. 2009. View Article : Google Scholar : PubMed/NCBI
9	Qiu G and Hill JS: Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol. 51:388–395. 2008. View Article : Google Scholar : PubMed/NCBI
10	Llaverias G, Noé V, Peñuelas S, Vázquez-Carrera M, Sánchez RM, Laguna JC, Ciudad CJ and Alegret M: Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun. 318:265–274. 2004. View Article : Google Scholar : PubMed/NCBI
11	Gómez-Hernández A, Sánchez-Galán E, Martín-Ventura JL, Vidal C, Blanco-Colio LM, Ortego M, Vega M, Serrano J, Ortega L, Hernández G, et al: Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization. J Cardiovasc Pharmacol. 47:60–69. 2006. View Article : Google Scholar : PubMed/NCBI
12	Jia F, Wu C, Chen Z and Lu G: AMP-activated protein kinase inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells. Cardiovasc Drugs Ther. 25:21–29. 2011. View Article : Google Scholar : PubMed/NCBI
13	Bao XM, Wu CF and Lu GP: Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling. Acta Pharmacol Sin. 30:1392–1398. 2009. View Article : Google Scholar : PubMed/NCBI
14	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Institutes of Health; The National Academies Press, Washington, DC: 2011
15	Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM and Taylor LM Jr: Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 40:873–881. 1994.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
17	Shah PK: Molecular mechanisms of plaque instability. Curr Opin Lipidol. 18:492–499. 2007. View Article : Google Scholar : PubMed/NCBI
18	Cavieres V, Valdes K, Moreno B, Moore-Carrasco R and Gonzalez DR: Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: Role for nitric oxide and interleukin-6. Am J Cardiovasc Dis. 4:114–122. 2014.PubMed/NCBI
19	McLaren JE, Michael DR, Ashlin TG and Ramji DP: Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog Lipid Res. 50:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
20	Vizzardi E, Cavazzana I, Sciatti E, Bonadei I, D'Aloia A, Tincani A, Franceschini F and Metra M: Evaluation of ascending aorta wall in rheumatoid arthritis by tissue and strain Doppler imaging during anti-tumor necrosis factor-α therapy. Clin Cardiol. 37:738–743. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lim HS and Lip GY: Circulating matrix metalloproteinase-9 levels in atherosclerotic vascular disease: A possible measurement of systemic or specific disease pathophysiology? J Intern Med. 263:620–622. 2008. View Article : Google Scholar : PubMed/NCBI
22	Galán M, Kassan M, Kadowitz PJ, Trebak M, Belmadani S and Matrougui K: Mechanism of endoplasmic reticulum stress-induced vascular endothelial dysfunction. Biochim Biophys Acta. 1843:1063–1075. 2014. View Article : Google Scholar : PubMed/NCBI
23	Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr and Davies PF: Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res. 105:453–461. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zhou AX and Tabas I: The UPR in atherosclerosis. Semin Immunopathol. 35:321–332. 2013. View Article : Google Scholar : PubMed/NCBI
25	Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, Cella M and Bernal-Mizrachi C: Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 287:11629–11641. 2012. View Article : Google Scholar : PubMed/NCBI
26	Myoishi M, Hao H, Minamino T, Watanabe K, Nishihira K, Hatakeyama K, Asada Y, Okada K, Ishibashi-Ueda H, Gabbiani G, et al: Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation. 116:1226–1233. 2007. View Article : Google Scholar : PubMed/NCBI
27	Song XJ, Yang CY, Liu B, Wei Q, Korkor MT, Liu JY and Yang P: Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 8:564–572. 2011. View Article : Google Scholar : PubMed/NCBI
28	Xia JG, Xu FF, Qu Y, Song DG, Shen H and Liu XH: Atorvastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress-related apoptosis. Shock. 42:365–371. 2014. View Article : Google Scholar : PubMed/NCBI